Table 2.
Patient characteristics and univariate analysis of malignant melanoma (n=105).
| Item | N (%) | Low unmet needs, 52 (49.5%) | High unmet needs, 53 (50.4%) | X2 | p |
|---|---|---|---|---|---|
| Gender | 6.070(1) | 0.014 | |||
| Male | 47 (44.8) | 17 (32.7%) | 30 (56.6%) | ||
| Female | 58 (55.2) | 35 (67.3%) | 23 (43.4%) | ||
| Age (years) | 3.677(1) | 0.159 | |||
| 25 ~ 44 | 17 (16.2) | 12 (23.1%) | 5 (9.4%) | ||
| 45 ~ 59 | 36 (34.3) | 17 (32.7%) | 19 (35.8%) | ||
| 60 ~ 84 | 52 (49.5) | 23 (44.2%) | 29 (54.7%) | ||
| Occupation | 14.132(1) | 0.003 | |||
| Manual worker | 14 (13.3) | 8 (15.4%) | 6 (11.3%) | ||
| Farmers | 55 (52.4) | 18 (34.6%) | 37 (69.8%) | ||
| Institutional employee | 17 (16.2) | 13 (25.0%) | 4 (7.5%) | ||
| Other | 19 (18.1) | 13 (25.0%) | 6 (11.3%) | ||
| Education level | 18.463(1) | <0.001 | |||
| Primary school or below | 37 (35.2) | 12 (23.1%) | 25 (47.2%) | ||
| Middle school | 35 (33.3) | 14 (26.9%) | 21 (39.6%) | ||
| High school/Vocational school | 21 (20.0) | 15 (28.8%) | 6 (11.3%) | ||
| Junior college or above | 12 (11.4) | 11 (21.2%) | 1 (1.9%) | ||
| Type of health insurance | 15.470(2) | <0.001 | |||
| New rural cooperative medical insurance | 69 (65.7) | 25 (48.1%) | 44 (83.0%) | ||
| Urban resident insurance | 10 (9.5) | 6 (11.5%) | 4 (7.5%) | ||
| Employee medical insurance | 26 (24.8) | 21 (40.4%) | 5 (9.4%) | ||
| Tumor location | 1.825(2) | 0.610 | |||
| Head and face | 11 (10.5) | 6 (11.5%) | 5 (9.4%) | ||
| Extremities | 63 (60.0) | 31 (59.6%) | 32 (60.4%) | ||
| Trunk | 9 (8.6) | 6 (11.5%) | 3 (5.7%) | ||
| Other | 22 (21.0) | 9 (17.3%) | 13 (24.5%) | ||
| Tumor stage | 3.959(2) | 0.164 | |||
| Stage I-II | 4 (3.8) | 4 (7.7%) | 0 | ||
| III | 55 (52.4) | 26 (50.0%) | 29 (54.7%) | ||
| IV | 46 (43.8) | 22 (42.3%) | 24 (45.3%) | ||
| Disease duration (years) | 0.462(1) | 0.794 | |||
| <1 | 25 (23.8) | 11 (21.2%) | 14 (26.4%) | ||
| 1 ~ 3 | 36 (34.3) | 19 (36.5%) | 17 (32.1%) | ||
| >3 | 44 (41.9) | 22 (42.3%) | 22 (41.5%) | ||
| Current treatment modality | 2.656(2) | 0.633 | |||
| Surgery | 44 (41.9) | 22 (42.3%) | 22 (41.5%) | ||
| Radiotherapy | 6 (5.7) | 3 (5.8%) | 3 (5.7%) | ||
| Chemotherapy | 15 (14.3) | 5 (9.6%) | 10 (18.9%) | ||
| Immunotherapy | 31 (29.5) | 18 (34.6%) | 13 (24.5%) | ||
| Targeted therapy | 9 (8.6) | 4 (7.7%) | 5 (9.4%) | ||
| Distant metastasis | 1.600(1) | 0.206 | |||
| No | 48 (45.7) | 27 (51.9%) | 21 (39.6%) | ||
| Yes | 57 (54.3) | 25 (48.1%) | 32 (60.4%) | ||
| Current primary source of health information | |||||
| (1) Internet-based channels | 34.568(1) | <0.001 | |||
| No | 64 (61.0) | 17 (32.7%) | 47 (88.7%) | ||
| Yes | 41 (39.0) | 35 (67.3%) | 6 (11.3%) | ||
| (2) Family/friends channels | 3.583(1) | 0.058 | |||
| No | 39 (37.1) | 24 (46.2%) | 15 (28.3%) | ||
| Yes | 66 (62.9) | 28 (53.8%) | 38 (71.7%) | ||
| (3) Healthcare provider channels | 0.401(1) | 0.527 | |||
| No | 25 (23.8) | 11 (21.2%) | 14 (26.4%) | ||
| Yes | 80 (76.2) | 41 (78.8%) | 39 (73.6%) |
(1) Asymptotic method was used for chi-square test; (2) Fisher’s exact test was used when expected cell frequencies were <5.